Could an antidepressant ease long COVID fatigue?
NCT ID NCT07359482
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether fluvoxamine, an antidepressant, can reduce severe fatigue and other symptoms in people with post-COVID. 160 adults aged 18-70 with long-lasting fatigue after COVID will receive either the drug or a placebo for 12 weeks. The goal is to see if it improves energy and thinking, and to understand how it works in the body.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 160 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2026
- Expected to finish
-
May 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults aged 18 to 70 years * Severely fatigued (CIS fatigue score ≥ 35) at screening * Fatigue started/increased significantly after Covid-19 (self-declared) * Fatigue symptoms must be present for at least 3 months following the acute infection. * Self-reported confirmation of having a SARS-CoV-2 infection by: Positive SARS-CoV-2 nucleic acid amplification test (NAAT), such as PCR; Positive SARS-CoV-2 rapid diagnostic test, including home-administered tests; COVID-19 diagnosis by a medical specialist (GP or in-hospital), based on the above or other clinical test or assessments. The above information will not be verified in medical records. * Command of Dutch or English language to complete questionnaires * Able to participate in video calling. * Willing and able to provide informed consent * Allowing the trial team to exchange medical information that is relevant for the participants' safety and trial assessments with their GP and pharmacy. Exclusion Criteria: * Use of medication with interaction with fluvoxamine that cannot be discontinued * Hospitalized in the acute phase of Covid-19 * Psychiatric/somatic disorders that could explain the severity of fatigue * Neurodegenerative disorders (i.e. M Parkinson, Multiple sclerosis, M Alzheimer) * Suicidality (current or recent) (according to WHO suicide screener) * Starting or started with other medication intended to reduce post-covid symptoms during the last 2 months * Pregnancy (a positive urine or serum pregnancy test) or unwilling to use standard contraception * Brugada- or Long QT interval syndrome * epilepsy, porphyria, history of severe liver impairment * known allergies to fluvoxamine or placebo/excipients * known current alcohol or drug use problems. * Bleeding disorders and past medical history of bleeding gastric or duodenal ulcers or other significant bleeding disorders * claustrophobia (optional MRI substudy) * having metal implants (optional MRI substudy) * inability to lay still for 45 minutes (optional MRI substudy) * Neurotrauma/ large stroke or brain abnormalities interfering with image analyses (optional MRI substudy) * Inability to come to the Amsterdam UMC (optional MRI substudy).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Post-COVID are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Amsterdam UMC
RECRUITINGAmsterdam-Zuidoost, 1105 AZ, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Zapping the brain to clear long COVID fog: a new hope?
- Diet and exercise may ease long COVID symptoms in obese veterans
- New program aims to help Long-COVID patients with online screening and personal support
- Breathing battle: which device helps CP Kids' lungs after COVID?
- Cold water splash: new study tests hydrotherapy for long COVID relief